Search by keywords: Connect with us Stay Informed. Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters. Newsletter Sign Up 1824 News Items found Clinical Update CAR T Cell Therapy for Light Chain (AL) Amyloidosis Achieves Strong Results Sunday, December 7, 2025 Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis. Article New Extramedullary Myeloma Treatment With Bispecific Antibodies Improves Survival Dramatically Sunday, December 7, 2025 Read about a new treatment combining bispecific antibodies that is effective against extramedullary myeloma. New Treatment for Relapsed Follicular Lymphoma Approved by FDA After MSK-Led Clinical Trial Sunday, December 7, 2025 A phase 3 trial led by MSK showed that adding epcoritamab to traditional treatment for follicular lymphoma benefits patients. Epcoritamab received FDA approval based on the findings. Cancer Care Worth Traveling For: Why People Come to MSK From Across the Country Thursday, December 4, 2025 Learn why over 5,000 people a year travel more than 150 miles to MSK for cancer care, including resources for the specific needs of traveling patients and their loved ones. Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs Wednesday, December 3, 2025 Learn what Zepbound, Wegovy, Ozempic and other weight loss drugs mean for cancer risk and treatment, from an expert at MSK. Q&A Meet Omar Abdel-Wahab: A 2025 Paul Marks Prize Recipient Monday, December 1, 2025 A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. FDA Approves Adding Durvalumab Immunotherapy to Prevent Stomach and Esophageal Cancer Recurrence Tuesday, November 25, 2025 Learn about a new approach helping to reduce the risk of stomach and esophageal cancer coming back after surgery, which has been approved by the FDA thanks to a clinical trial with immunotherapy led by researchers at MSK. Able To Speak After Tongue Cancer, Thanks to a Second Opinion at MSK and a Partial Glossectomy Monday, November 24, 2025 Thanks to a second opinion and minimally invasive surgery at MSK to remove tongue cancer, Karren Tyler is back home in Charlottesville, Virginia, cancer free and focused on giving back to other cancer patients. FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based on Trial Led by MSK Researcher Thursday, November 20, 2025 The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK. Feature How To Stop the Fear of Cancer Thursday, November 20, 2025 Learn more about five essential strategies for coping with the fear of cancer, from MSK psychiatrist Dr. Monique James. Pagination Load More Book traversal links for Newsroom Previous Newsroom Next Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment